BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaltsas G, Grossman AB. The expanding role of somatostatin analogues in the treatment of neuroendocrine tumours: the CLARINET study. Clin Endocrinol (Oxf). 2015;83:759-761. [PMID: 26052840 DOI: 10.1111/cen.12831] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Cavalcoli F, Rausa E, Conte D, Nicolini AF, Massironi S. Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies? World J Gastroenterol 2017; 23(15): 2640-2650 [PMID: 28487601 DOI: 10.3748/wjg.v23.i15.2640] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
2 Gut P, Waligórska-Stachura J, Czarnywojtek A, Sawicka-Gutaj N, Bączyk M, Ziemnicka K, Fischbach J, Woliński K, Kaznowski J, Wrotkowska E, Ruchała M. Management of the hormonal syndrome of neuroendocrine tumors. Arch Med Sci 2017;13:515-24. [PMID: 28507564 DOI: 10.5114/aoms.2016.60311] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
3 Neychev V, Kebebew E. Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. Int J Surg Oncol 2017;2017:6424812. [PMID: 28593056 DOI: 10.1155/2017/6424812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Albertelli M, Nazzari E, Sciallero S, Grillo F, Morbelli S, De Cian F, Cittadini G, Ambrosetti E, Ciarmiello A, Ferone D; IRCCS Policlinico San Martino, University of Genova Neuroendocrine Tumor Board. Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. J Endocrinol Invest 2017;40:1265-9. [PMID: 28550464 DOI: 10.1007/s40618-017-0692-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Tadman M, Charlton P, Jafar-Mohammadi B, Talbot D, Grossman AB. INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE. Endocr Pract 2018;24:189-94. [PMID: 29466059 DOI: 10.4158/EP-2017-0137] [Reference Citation Analysis]
6 Demirci E, Kabasakal L, Toklu T, Ocak M, Şahin OE, Alan-Selcuk N, Araman A. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update. Nucl Med Commun 2018;39:789-96. [PMID: 29912750 DOI: 10.1097/MNM.0000000000000874] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]